TP53 and ovarian cancer: Development in this area lead to the design of OxaliTEX, a texaphyrin based oxaliplatin drug conjugate (Fig. 19).150 Here the inclusion of the diaminocyclohexane ligand produced a molecule that could overcome the resistance mechanisms of platin-resistant wild type p53 ovarian cancer cells via ribosomal stress induction.